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Cardiovascular events and bleeding risk associated with intravitreal anti-VEGF monoclonal antibodies: systematic review and meta-analysis Marie Thulliez (1), Denis Angoulvant (2), Marie Laure Le Lez (1), AnniePierre Jonville-Bera (3), Pierre-Jean Pisella (1), François Gueyffier (4), Theodora Bejan-Angoulvant (5) (1) CHRU Tours, Université F.Rabelais, Ophtalmologie, Tours, CHRU Tours, Université F.Rabelais, USCI Cardiologie, Tours, CHRU Tours, Pharmacologie, Tours, Few data exists regarding the systemic safety of intravitreal anti-VEGF monoclonal antibodies (MAb) use in people with neovascular age-related macular degeneration (AMD), diabetic macular oedema (DMO) or retinal vein occlusions (RVO). We performed a systematic review and meta-analysis to evaluate the risk of major cardiovascular (MCE) and nonocular hemorrhagic (NHE) events in AMD, DMO or RVO patients receiving intravitreal anti-VEGF MAb. We included randomized controlled trials (RCT) comparing ranibizumab or bevacizumab to no treatment or non-anti-VEGF treatments, or ranibizumab to bevacizumab, in AMD, DMO or RVO patients. We used fixed effect model and reported results as odds-ratios and their 95% CI. Primary endpoints were major cardiovascular and nonocular hemorrhagic events. Conclusions: the available clinical evidence showed that anti-VEGFMAbs were not associated with significant increases in risks of MCE or NHE, but studies and meta-analysis were not powered enough to correctly assess these risks. Increased risks of VTE with bevacizumab and nonocular hemorrhagic events in older AMD patients with ranibizumab should also be cautiously interpreted, as more safety data are needed
Results
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Is the measurement of carotid-femoral pulse wave velocity useful in patients with peripheral artery disease?
Victor Aboyans (1), Aida Oueslti (2), Ileana Desormais (2), Thomas Cautres (1), Philippe Lacroix (2) (1) CHU Limoges, Cardiologie, Limoges, France -(2) CHU Limoges, Hôpital Dupuytren, CTCV, Limoges, France Purpose: The carotid-femoral pulse-wave velocity (cfPWV) is predictive for cardiovascular events in general population and in patients with coronary artery disease (CAD). Patients with peripheral artery disease (PAD) are high cardiovascular risk, but the interest of cfPWV has never been assessed in this case. We sought to compare cfPWV in severe cases of PAD and CAD, and to assess its prognostic value in the former group.
Methods:
From 01/12 to 06/13 we measured cfPWV in patients referred to our hospital either for CABG or for limb revascularization for severe PAD. Patients with CAD with ankle-brachial index <0.90 were excluded. In PAD patients, baseline data and risk factors were compared in those with cfPWV>10m/s vs. those ≤10m/s. During follow-up, the following outcomes were collected: death, amputation and MACE (death, or stroke or myocardial infarction).
Results:
We studied 162 patients (76 with PAD and 86 with CAD, age 69 vs. 67 yrs, p=0.25), with similar sex and risk factors distribution, except for diabetes (54% vs 20%, p<0.05). PAD patients had higher cfPWV than those with CAD (11.3±3.7 vs. 9.8±3.0m/s, p<0.007). In patients with PAD, 50% had a cfPWV>10m/s. These patients were older (72 vs. 66 yrs, p<0.001) with higher rates of diabetes (76% vs 56%, p<0.001) than PAD patients with cfPWV ≤10m/s, but did not differ regarding other risk factors. The cfPWV was found lower in the presence of aorto-iliac disease than in case of more distal PAD (9.5±2.5 vs. 11.8±3.9m/s, p<0.001). During follow-up of 10.5±5.7 months of PAD patients, 17.1% deceased, 5.3% had amputation, and MACE occurred in 19.7% of cases. We found no association between cfPWV and events (HR for death: 0.95, p=0.28; HR for amputation: 1.02, p=0.65; HR for MACE: 0.98, p=0.29) .
Conclusion:
Patients with PAD have stiffer aorta than those with CAD, as assessed by cfPWV, in part due to higher rates of diabetes. However cfPWV is not prognostic in patients PAD. The lower cfPWV in patients with aortoiliac disease may suggest measurement issues, as this velocity may be decreased because of severe stenosis on the pulse wave trajectory. 
